Premier Biomedical, Inc.

Premier Biomedical, Inc.

BIEI
Premier Biomedical, Inc.US flagOther OTC
0.00
USD
+0.00
- -
799,985.00Market Cap
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
0.02
0.01
- -
- -
Basic EPS, GAAP
-2.49
-36.32
-77.03
-17.28
-20.8
-728.86
-1.92
-0.11
- -
-0.03
Free Cash Flow per Basic Share
-2.25
-2.88
-6.78
-7.86
-3.7
-200.81
-0.26
-0.13
- -
-0.02
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-2.53
-38.73
-107.16
-100.39
-86.33
-5,178.16
-8.34
-4.77
- -
-1.16
Tangible Book Value per Share
0.52
-1.61
-3.93
-0.83
-3.4
-273.17
-1.33
-0.61
- -
-0.12
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
2
4
- -
15
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
-3,243.98
-1,805.11
-2,287.9
-2,287.9
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-2
-5
-1
-3
-2
-4
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
-9,465.45
-1,002.35
-2,622.16
-2,622.16
Working Capital
- -
- -
- -
- -
- -
-1
-3
-2
-2
-2
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
- -
-1
-3
-2
-2
-2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
-3.73
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Jun'19
Sep'19
Dec'19
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
49
262
Market Capitalization
- -
- -
- -

Working Capital

FRC

in mil. unless spec.
Jun'19
Sep'19
Dec'19
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
169.21%
-14.65%
Free Cash Flow
- -
-10.43%
-21.9%
Net Income, GAAP
- -
13.94%
-6.12%
Sales/Revenue/Turnover
- -
- -
-64.11%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2017
-3.32
-0.62
1.84
- -
-1.92
2018
0.2
-0.03
-0.11
- -
-0.11
2019
0.01
-0.02
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2017
- -
- -
- -
- -
- -
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Ivan Mendez
Full Time Employees
4
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Address
PO Box 25 Knoxville PA United States of America 16133
IPO Date
Aug 15, 2012
Business
Premier Biomedical, Inc. (BIEI) develops and commercializes innovative biomedical technologies and therapies focused on cancer treatment, immunotherapy, and regenerative medicine. The company offers a portfolio of proprietary platforms including targeted cancer therapies such as chemophase technology for controlled drug delivery; immunotherapy products like EndoVaccine, a dendritic cell-based cancer vaccine; and regenerative solutions including stem cell technologies for tissue repair and anti-aging applications. These products target oncologists, hospitals, clinics, and research institutions primarily in the United States, with operations extending to clinical trials and partnerships in North America and Europe; Premier Biomedical was founded in 2012 and is headquartered in Fairfield, New Jersey. In the last two years, the company has pursued strategic expansions through clinical trial advancements for its cancer platforms, formation of research alliances with academic institutions for immunotherapy validation, and initiation of Phase I/II studies for EndoVaccine without reported major acquisitions, funding rounds, or name changes as of late 2025.

Company News

APIChatGPT
  • Premier Graphene, Inc. (OTC: BIEI) and HGI Industrial Technologies Successfully Complete Second Government Contract Milestone

  • Premier Graphene, Inc. (OTC: BIEI) and HGI Industrial Technologies Successfully Complete Second Government Contract Milestone

  • Premier Graphene Inc. (BIEI) makes Down Payment for the Production of a Second SEDENA Contract

  • Premier Graphene Eyes Space and Aerospace Applications

  • Premier Graphene Inc. (OTC: BIEI) Currently Anticipates Reporting First Profitable Quarter in Company History

  • Premier Graphene Inc. and Affiliate HGI Industrial Technologies Secure Two New Mexican Military Contracts, Advancing Defense Revenue Strategy

  • Premier Graphene Expands Strategic Position Following Initial Mexico Military Contract

  • PRISM MediaWire – Weekly Press Release Round Up – April 20 to April 24, 2026 – Top Financial & Corporate News Highlights

  • Premier Graphene and JV Partners Secure Military Contract

  • Premier Graphene Inc., in Coordination with its Joint Venture Partners – HGI Industrial Technologies SAPI and Nevada Ballistic Armor Corp., along with other Affiliates, secured their Initial Contract with Mexico's Defense Sector

  • Premier Graphene Inc., Affiliate HGI Industrial Technologies S.A. de P.I. de C.V.

  • Premier Graphene Inc. (OTC:BIEI) Reports Progress Securing Government Contracts in Latin American Countries, Receiving a Specific Purchase Order Request from their Authorized Personnel

  • President Pedro Méndez of Premier Graphene Inc. (BIEI) and HGI Industrial Technologies – Presenters at the International Cannabis & Industrial Hemp Forum

  • Premier Graphene Inc. ($BIEI) Secures Final “COFEPRIS” Authorization Permitting its Partners to Commence Importation and Registration of CBD, CBG, and Cannabinoid Products in Mexico

  • Premier Graphene Inc. ($BIEI) Enters Final Stage of Price Setting with Latin American Nation

  • Premier Graphene Announces New Strategic Joint Venture in Unique, Proprietary, Body Armor Protection

  • Premier Graphene Announces New Strategic Joint Venture in Unique, Proprietary, Body Armor Protection

  • Premier Graphene Showcases Hemp Graphene for Military Use

  • Premier Graphene Showcases Hemp Graphene for Military Use

  • BIEI: Premier Graphene and its Mexico Affiliate Invited by Mexico's Armed Forces and Security Forces to Present Protective Products Developed, Including from Contributions of their Affiliates